Tebentafusp

Unassigned

New Medicines

Uveal melanoma

Information

New molecular entity
Immunocore
Immunocore

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase II Clinical Trials
Yes

Category

First-in-class bi-specific T cell redirector. It binds to a melanocyte-associated target peptide of gp100 presented on the surface of melanoma cells by Human Leukocyte Antigen molecules; once bound it redirects CD-3 positive T cells to kill cancer cells
Uveal melanoma (UM) is a serious life-threatening intraocular malignancy, primarily involving the choroid (90%), ciliary body (7%) or iris (2%). 98% of cases occur in Caucasians [1]. UM is the most common primary intraocular malignancy in adults, representing 3%–5% of all melanomas. Incidence varies by sex, race, and country. In Europe, incidence increases with latitude, ranging from 2 per million in Spain and Italy, 4-6 per million in Central Europe, and >8 per million in Denmark & Norway [2].
Uveal melanoma
Intravenous infusion

Evidence based evaluations